Disease/Infection News

RSS

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Public restrooms could serve as hotbeds for COVID-19 transmission

Flushing a toilet can generate large quantities of microbe-containing aerosols depending on the design, water pressure or flushing power of the toilet. A variety of pathogens are usually found in stagnant water as well as in urine, feces and vomit.

20 Apr 2021

New mathematical model could help design new probiotics and tailored diets to prevent diseases

A new mathematical model for the interaction of bacteria in the gut could help design new probiotics and specially tailored diets to prevent diseases. The research, from Chalmers University of Technology in Sweden, was recently published in the journal PNAS.

20 Apr 2021

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study published in Frontiers in Immunology.

20 Apr 2021

Eviction bans authorized during COVID-19 pandemic reduced the infection rate, indicates study

A new study led by researchers at Johns Hopkins and the University of Pennsylvania uses computer modeling to suggest that eviction bans authorized during the COVID-19 pandemic reduced the infection rate and not only protected those who would have lost their housing but also entire communities from the spread of infections.

20 Apr 2021

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time--a tool that could someday help public health officials combat misinformation online.

20 Apr 2021

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Ensuring COVID-19 vaccine access for refugee and displaced populations, and addressing health inequities, is vital for an effective pandemic response.

20 Apr 2021

Use of ozone as a decontaminant for SARS-CoV-2

Researchers in Germany have demonstrated how an ozone-based decontamination device significantly reduces the volume of viral residue left on surfaces of two surrogate viruses for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Apr 2021

Screening drug candidates for COVID-19 treatment using computational methods

Researchers identified two potential drug candidates that can inhibit SARS-CoV-2 in vitro. Their combination can work synergistically and increase their inhibitory effect.

19 Apr 2021

New infectious hospital framework employs robotic tools for pandemic mitigation

In December 2019, a new viral infection was detected in Wuhan, China. On January 30, 2020, the World Health Organization declared the outbreak a public health emergency of international concern, and on March 11, the COVID-19 pandemic.

19 Apr 2021

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

CoronaVac is a well-tolerated vaccine containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it induced humoral responses in phase 1 and 2 studies. Analysis of a Brazilian phase 3 clinical trial that evaluated 12,607 participants showed that the vaccine had an efficacy of 50.39% 15 days after the 2nd dose.

19 Apr 2021

Study identifies COVID-19 vaccine inequity in Massachusetts

A new study led by Bisola O. Ojikutu of Brigham and Women’s Hospital in Boston suggests not only do these communities have a higher infection, but they are also experiencing lower vaccine distribution. The team suggests that reformation for equitable vaccine delivery is necessary to eliminate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

COVID-19 patients who are overweight or obese may develop a more severe infection

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mechanical ventilation more often. There is no increased risk of death .

19 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Chemical biomarker could be used to better manage treatments for COVID-19

Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations.

19 Apr 2021

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Disease/Infection News

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Public restrooms could serve as hotbeds for COVID-19 transmission

New mathematical model could help design new probiotics and tailored diets to prevent diseases

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Eviction bans authorized during COVID-19 pandemic reduced the infection rate, indicates study

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Use of ozone as a decontaminant for SARS-CoV-2

Screening drug candidates for COVID-19 treatment using computational methods

New infectious hospital framework employs robotic tools for pandemic mitigation

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

Study identifies COVID-19 vaccine inequity in Massachusetts

COVID-19 patients who are overweight or obese may develop a more severe infection

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Chemical biomarker could be used to better manage treatments for COVID-19

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers manufacture the SARS-CoV-2 RBD in pichia

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest News